![]() |
½ÃÀ庸°í¼
»óǰÄÚµå
1654365
¹Ì±¹ÀÇ ÆÄŲ½¼º´¿ë ³ú½ÉºÎ ÀÚ±Ø ½ÃÀå ±Ô¸ð, Á¡À¯À², µ¿Ç⠺м® º¸°í¼ : Á¦Ç°º°, °æÀï ºÐ¼®, ºÎ¹®º° ¿¹Ãø(2025-2030³â)U.S. Deep Brain Stimulation In Parkinson¢¥s Disease Market Size, Share & Trends Analysis Report By Product (Single-channel, Dual-channel), Competitive Analysis, And Segment Forecasts, 2025 - 2030 |
Grand View Research, Inc.ÀÇ ÃֽŠº¸°í¼¿¡ µû¸£¸é ¹Ì±¹ÀÇ ÆÄŲ½¼º´¿ë ³ú½ÉºÎ ÀÚ±Ø ½ÃÀå ±Ô¸ð´Â 2025-2030³â ¿¬Æò±Õ 7.19%ÀÇ ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR)À» º¸À̰í, 2030³â¿¡´Â 8¾ï 4,950¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
ÀÌ ½ÃÀåÀº ½ÅÁ¦Ç° Ãâ½Ã, ÀÇ·áºñ Áõ°¡ µî ´Ù¾çÇÑ ¿äÀο¡ ÀÇÇØ ÁÖµµµÇ°í ÀÖ½À´Ï´Ù. ±ÔÁ¦ ´ç±¹ÀÇ ½ÂÀÎ Áõ°¡´Â ÀÇ·áÁø°ú ȯÀÚ¿¡°Ô ÀÌ·¯ÇÑ ±â±âÀÇ ¾ÈÀü¼º°ú À¯È¿¼º¿¡ ´ëÇÑ º¸ÁõÀ» Á¦°øÇÏ¿© ÀÓ»ó ÇöÀå¿¡¼ÀÇ Ã¤ÅÃÀ» ÃËÁøÇϹǷΠ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÏ´Â µ¥ Áß¿äÇÑ ¿ªÇÒÀ» Çϰí ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î 2024³â 1¿ù AbbottÀÇ Liberta RC DBS ±â±âÀÇ FDA ½ÂÀÎÀº PD Ä¡·á ÁßÀ縦 ÁøÀü½ÃŰ´Â Áß¿äÇÑ ÀÌÁ¤Ç¥°¡ µÇ¾ú½À´Ï´Ù.
¸®¹öŸ RC DBS´Â µ¿±Þ ÃÖ¼ÒÇü ÃæÀü½Ä DBS Àåºñ·Î ÁÖ¸ñ¹Þ°í ÀÖÀ¸¸ç, ¿ø°Ý ÇÁ·Î±×·¡¹Ö ±â´ÉÀ» °¡´ÉÇÏ°Ô ÇÏ´Â NeuroSphere Virtual Clinical°ú °°Àº ÁÖ¸ñÇÒ ¸¸ÇÑ ±â¼úÀû Ư¡À» µµÀÔÇß½À´Ï´Ù. À̹ø ±ÔÁ¦ ´ç±¹ÀÇ ½ÂÀÎÀº ÀÌ Àåºñ°¡ ¾ö°ÝÇÑ ¾ÈÀü¼º°ú À¯È¿¼º ±âÁØÀ» ÁؼöÇϰí ÀÖÀ½À» °Á¶Çϸç, ½Å°æÁ¶Àý ºÐ¾ßÀÇ ¼±±¸ÀûÀÎ ¼Ö·ç¼ÇÀ¸·Î ÀÚ¸®¸Å±èÇϰí ÀÖ½À´Ï´Ù. Abbott°¡ ¸®¹öŸ RC DBS¿¡ ¿ø°Ý ÇÁ·Î±×·¡¹Ö ±â´ÉÀ» Ãß°¡ÇÑ °ÍÀº ÀϹÝÀûÀÎ ÀÇ·á µ¿Çâ¿¡ Àü·«ÀûÀ¸·Î ºÎÇÕÇÏ´Â °ÍÀ¸·Î, ȯÀÚÀÇ ÆíÀǼºÀ» ³ôÀ̰í ÀÇ·á°èÀÇ ¼ö¿ë¼ºÀ» È®´ëÇÒ ¼ö ÀÖÀ» °ÍÀ¸·Î ±â´ëµË´Ï´Ù.
ÃÖ±Ù Abbott»ç°¡ Liberta RC DBSÀÇ FDA ½ÂÀÎÀ» ȹµæÇÔ¿¡ µû¶ó ½ÃÀå ¿ªÇп¡ º¯È¸¦ °¡Á®¿Í ¹Ì±¹³» PD Ä¡·á¿ë DBS ºÐ¾ß¿¡ ´ëÇÑ °ü½ÉÀÌ ³ô¾ÆÁ® µµÀÔÀÌ ÃËÁøµÉ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
The U.S. deep brain stimulation in parkinson's disease market size is anticipated to reach USD 849.50 million by 2030, registering a CAGR of 7.19% from 2025 to 2030, according to a new report by Grand View Research, Inc. The market is driven by various factors, such as novel product launches, and rising healthcare expenditure. Increasing regulatory approvals play a crucial role in driving market growth as they provide a level of assurance to healthcare professionals and patients regarding the safety and efficacy of these devices, thereby encouraging their adoption in clinical practice. For instance, in January 2024, FDA clearance for Abbott's Liberta RC DBS Device represented a significant milestone in advancing therapeutic interventions for PD.
Liberta RC DBS, distinguished as the smallest rechargeable DBS device in its class, introduced notable technological features, such as the NeuroSphere Virtual Clinical, enabling remote programming capabilities. This regulatory endorsement underscored adherence of the device to stringent safety and efficacy standards and positioned it as a pioneering solution in the field of neuromodulation. The incorporation of remote programming capabilities in the Liberta RC DBS device by Abbott aligns strategically with prevailing healthcare trends, augmenting patient convenience and broadening the device's acceptance within the medical community.
Abbott's recent achievement of securing FDA clearance for Liberta RC DBS is anticipated to catalyze transformative shifts in market dynamics, propelling heightened interest and fostering increased adoption within the U.S. DBS sector for PD treatment.